A study by researchers at York University in Toronto has found that nirsevimab, which is given before the start of first respiratory syncytial virus season, can help youngsters to avoid severe lung infections that often lead to hospitalization and death. As a one-time, lower- cost option, nirsevimab should streamline administration process, while also being “highly…